Modality
Nanobody
MOA
CDK4/6i
Target
FLT3
Pathway
Fibrosis
Endometrial CaFTD
Development Pipeline
Preclinical
~Aug 2020
→ ~Nov 2021
Phase 1
Feb 2022
→ Dec 2031
Phase 1Current
NCT03277870
2,814 pts·Endometrial Ca
2022-02→2028-02·Active
NCT08797737
1,378 pts·Endometrial Ca
2024-07→2031-12·Terminated
4,192 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-02-241.9y awayInterim· Endometrial Ca
2031-12-245.7y awayInterim· Endometrial Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Active
P1
Termina…
Catalysts
Interim
2028-02-24 · 1.9y away
Endometrial Ca
Interim
2031-12-24 · 5.7y away
Endometrial Ca
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03277870 | Phase 1 | Endometrial Ca | Active | 2814 | DAS28 |
| NCT08797737 | Phase 1 | Endometrial Ca | Terminated | 1378 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET |